Transdermal Drug Delivery System Market by Type, Application, End User

Description

List of Tables

[180 Pages Report] The Transdermal Drug Delivery System Market size was estimated at USD 6.98 billion in 2023 and expected to reach USD 7.32 billion in 2024, at a CAGR 5.06% to reach USD 9.87 billion by 2030.

Transdermal drug delivery comprises the production, distribution, and application of therapeutic methods that facilitate the controlled release of medications through the skin. This innovative approach offers numerous advantages over conventional oral or intravenous drug administration, such as increased patient compliance, reduced side effects, and improved pharmacokinetic profiles. The TDDS encompasses various technologies, including passive diffusion systems, iontophoresis, microneedles, and ultrasound-mediated techniques. The increase in the aging population and the growing prevalence of chronic diseases necessitate more practical and convenient drug delivery methods. Furthermore, advancements in nanotechnology and materials science have enabled the development of sophisticated transdermal patches that offer superior drug permeation across biological membranes without causing irritation or discomfort to patients. However, high development costs associated with producing complex transdermal systems and incidences of product recalls may adversely impact their use in the healthcare sector. Besides, advanced drug delivery vehicles demonstrate promising potential to improve the bioavailability and solubility of water-soluble drugs, enabling more effective transdermal drug delivery strategies.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.98 billion
Estimated Year [2024]	USD 7.32 billion
Forecast Year [2030]	USD 9.87 billion
CAGR (%)	5.06%

Type: Ongoing regulatory and government approvals for transdermal patches

Transdermal patches are adhesive-coated, medicated patches designed to deliver a specific drug dosage through the skin and into the bloodstream over an extended period. They offer several advantages over conventional oral and parenteral drug delivery systems, such as improved patient compliance, reduced side effects, and controlled release of active ingredients. Drug-in-adhesive patches, matrix patches, microneedle patches, and reservoir membrane patches are available and are used according to medical requirements. The preference for transdermal patches is mainly due to their non-invasive nature and ease of application. They are suitable for patients experiencing difficulties swallowing pills or for those with gastrointestinal issues that may affect the absorption of medications. Transdermal semisolids include gels, creams, and ointments formulated with drugs that are absorbed through the skin into the systemic circulation. These dosage forms offer benefits such as easy application and removal, localized treatment without systemic side effects for certain conditions, and flexibility in formulation. Transdermal patches provide more consistent drug release than semisolids since they possess a controlled-release mechanism. Additionally, patches show better adhesion to the skin surface than semisolids, which may require frequent reapplication of the gels or creams.

Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases

Transdermal drug delivery systems are preferred in treating cardiovascular diseases such as angina pectoris or hypertension due to their ability to maintain constant plasma medication levels with fewer side effects. Nitroglycerin patches have been extensively used for angina patients, offering continuous relief without the need for frequent oral administration. TDDS displays an enhanced potential in managing central nervous system disorders, including Parkinson's disease and Alzheimer's disease, by maintaining steady concentrations of drugs. The continuous delivery minimizes fluctuations observed with oral medications, which can lead to breakthrough symptoms or side effects. Hormonal applications of TDDS include contraception, hormone replacement therapy (HRT), and testosterone supplementation. Transdermal patches offer advantages in maintaining steady hormone levels, reducing side effects, and improving patient compliance. Transdermal systems have gained popularity in managing chronic pain conditions, including musculoskeletal disorders or cancer-related pain, due to their ability to deliver analgesics directly to the affected area for long durations while minimizing systemic side effects. Transdermal estrogen therapy is essential for hormone replacement therapy for menopausal symptoms or osteoporosis management in postmenopausal women.

End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings

Transdermal drug delivery systems are being utilized within particular innovative clinics for skin care and are implemented into the more effective health care system. With the growing understanding of drug delivery and the continued efforts of medical doctors, engineers, and scientists to advance this technology, an ultrasound-based transdermal delivery platform is expected to be a step closer to clinical applications. Clinical impact relies on a transdermal delivery system that administers drugs safely and effectively, is low-cost and easy to use, and is designed for self-administration at home. Transdermal drug delivery has recently gained popularity due to its unique and advantageous properties, which provide prospective benefits over conventional routes of drug administration in the therapy of numerous illnesses in hospital settings. Hospitals and clinics serve several patients in rural regions, particularly senior populations. These pharmacists help patients at a higher risk of medication interactions or illness complications due to a lack of control over their condition.

Regional Insights

The transdermal drug delivery market is evolving in the Americas due to its well-established healthcare infrastructure and research & development activities. Regulatory bodies in the Americas ensure adherence to standard guidelines while approving new products, resulting in the development of innovative transdermal technologies. The APAC region has a growing demand for advanced healthcare technologies due to increasing disposable incomes, population aging, and the need for efficient treatments. The transdermal drug delivery system market is growing in the EMEA region due to the presence of pharmaceutical industries, increased healthcare spending, and the rapid expansion of its manufacturing capabilities for transdermal systems. Moreover, the increasing adoption of personalized medicine and targeted therapies presents further prospects for TDDS systems tailored to specific patient populations or disease conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Transdermal Drug Delivery System Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Transdermal Drug Delivery System Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AdhexPharma, SAS, Bayer AG, Biotts Inc., Boehringer Ingelheim International GmbH, DuPont de Nemours, Inc., Gensco Pharma, Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, IntelGenx Corp., Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Lavipharm S.A., Lead Chemical Co., Ltd., Luye Life Sciences Group, Medherant Limited, Nitto Denko Corporation, Novartis International AG, Nutriband Inc., Purdue Pharma L.P., Sorrento Therapeutics, Inc., Sparsha Pharma International Pvt. Ltd., Starton Therapeutics, Toa Eiyo Ltd., Toyo Ink SC Holdings Co., Ltd., Transdermal Therapeutics, Inc., UCB S.A., Viatris Inc., Zhongshan Senwell Bio Technology Co., Ltd., and Zynerba Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Transdermal Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Transdermal Patches
  - Drug-In-Adhesive Patches
  - Matrix Patches
  - Microneedle Patches
  - Reservoir Membrane Patches

Transdermal Semisolids
- Gels
- Ointments
- Sprays

Application
- Cardiovascular Diseases
- Central Nervous System Disorders
- Hormonal Applications
- Pain Management
- Transdermal Estrogen Therapy

End User
- Home Care Settings
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Transdermal Drug Delivery System Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Transdermal Drug Delivery System Market?

3. What are the technology trends and regulatory frameworks in the Transdermal Drug Delivery System Market?

4. What is the market share of the leading vendors in the Transdermal Drug Delivery System Market?

5. Which modes and strategic moves are suitable for entering the Transdermal Drug Delivery System Market?

Product Code: MRR-433C4187C49A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of chronic diseases and the need for effective drug delivery
  - 5.1.1.2. Surging adoption of third-generation transdermal drug delivery system
- 5.1.2. Restraints
  - 5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research & development in transdermal drug delivery system
  - 5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
- 5.1.4. Challenges
  - 5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
5.2. Market Segmentation Analysis
- 5.2.1. Type: Ongoing regulatory and government approvals for transdermal patches
- 5.2.2. Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases
- 5.2.3. End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings
5.3. Market Trend Analysis
- 5.3.1. Potential power of market players and surge in regulatory approvals in the American region
- 5.3.2. Surging healthcare spendings and inclusion of overseas players in the APAC region
- 5.3.3. Persistent research activities and the growing burden of chronic disease in the EMEA region.
- 5.3.4. Revolutionizing transdermal drug delivery with electronic skin
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis

6. Transdermal Drug Delivery System Market, by Type

6.1. Introduction
6.2. Transdermal Patches
6.3. Transdermal Semisolids

7. Transdermal Drug Delivery System Market, by Application

7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Central Nervous System Disorders
7.4. Hormonal Applications
7.5. Pain Management
7.6. Transdermal Estrogen Therapy

8. Transdermal Drug Delivery System Market, by End User

8.1. Introduction
8.2. Home Care Settings
8.3. Hospitals & Clinics

9. Americas Transdermal Drug Delivery System Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Transdermal Drug Delivery System Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Transdermal Drug Delivery System Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
- 12.3.2. Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device
- 12.3.3. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
- 12.3.4. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
- 12.3.5. Zydus Lifesciences gets Final Approval from the U.S. FDA to Market Estradiol Transdermal System
- 12.3.6. Kindeva Merges with Meridian to Create Global CDMO Specializing in Drug-Device Combinations
- 12.3.7. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
- 12.3.8. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
- 12.3.9. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer's Dementia
- 12.3.10. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio